Compare Alcon AG (ALC) vs Oklo Inc (OKLO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs Oklo Inc — how do they compare? Alcon AG trades at $66.89 (market cap $32.69B), while Oklo Inc trades at $47.1 (market cap $8.33B). The key difference: Alcon AG is far larger — about 3.9× Oklo Inc's market cap, and Alcon AG pays a 0.54% dividend while Oklo Inc pays none. Which is the better fit depends on your goals.
| ALC | OKLO | |
|---|---|---|
Market Cap | $32.69B | $8.33B |
Sector | Health | Technology |
52-Week High | $92.22 | $174.14 |
52-Week Low | $62.02 | $45.58 |
Enterprise Value | $36.28B | $6.13B |
Dividend Yield | 0.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
OKLO trades at $51.84, down 0.99% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $105.66 million for 2025 and negative cash flow from operations. Recent positive developments include DOE safety approval for its Groves Isotope Test Reactor and strategic acquisitions to accelerate reactor development.
Analyst consensus remains strongly bullish with a $96 price target, but execution risks and sustained losses pose challenges. The stock's outlook hinges on successful reactor deployment and achieving profitability amid high cash burn. Investors should weigh the high growth potential against substantial operational and regulatory hurdles.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Oklo Inc
Oklo Inc. is a company focused on developing and commercializing advanced fission power plants. The company specializes in micro-reactor technology, specifically the Aurora design, which uses advanced fuel to produce reliable, clean, and cost-competitive power. Oklo aims to provide scalable, on-site power solutions to various customers, including remote communities, industrial facilities, and government entities, positioning itself as an innovator in the next generation of nuclear energy.
Read more on OKLO →
